Tang Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Tang Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$221M	Buy	13,044,106 +814,606	+7%	+$13M	10.05%	1
2026 Q1	$181M	Buy	12,229,500 +900,000	+8%	+$13.2M	9.2%	1
2025 Q4	$181M	Hold	11,329,500	–	–	8.93%	1
2025 Q3	$125M	Buy	11,329,500 +1,300,000	+13%	+$14.2M	4.82%	3
2025 Q2	$84.9M	Hold	10,029,500	–	–	4.29%	3
2025 Q1	$80.6M	Buy	10,029,500 +1,600,000	+19%	+$13M	4.46%	3
2024 Q4	$75.7M	Buy	8,429,500 +1,200,000	+17%	+$9.79M	5.01%	2
2024 Q3	$53M	Buy	7,229,500 +4,450,000	+160%	+$27.6M	3.79%	3
2024 Q2	$15.9M	Buy	2,779,500 +729,500	+36%	+$3.84M	1.62%	19
2024 Q1	$10.3M	Buy	2,050,000 +1,500,000	+273%	+$10.2M	1.07%	31
2023 Q4	$4.94M	Sell	550,000 -200,000	-27%	-$1.65M	0.46%	56
2023 Q3	$5.83M	Buy	750,000 +600,000	+400%	+$5.87M	0.82%	38
2023 Q2	$1.45M	Buy	+150,000	New	+$1.56M	0.21%	76
2023 Q1	–	Sell	-200,000	Closed	-$864K	–	106
2022 Q4	$864K	Hold	200,000	–	–	0.13%	71
2022 Q3	$1.5M	Buy	+200,000	New	+$1.73M	0.18%	75

Other funds holding AUPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Tang Capital Management's AUPH Position: Q2 2026 in Review

Tang Capital Management increased its Aurinia Pharmaceuticals (AUPH) stake by 6.7% in Q2 2026, buying an estimated $13M and bringing the position to 13,044,106 shares worth $221M. The position accounts for 10.05% of the portfolio, ranked #1.

Tang Capital Management first reported a position in AUPH in Q3 2022 and has held it in 15 quarters since. 281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Tang Capital Management held 13,044,106 shares of Aurinia Pharmaceuticals worth $221M as of Q2 2026.
Tang Capital Management bought 814,606 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $13M.
Aurinia Pharmaceuticals made up 10.05% of Tang Capital Management's portfolio in Q2 2026, its #1 holding.
Tang Capital Management first reported a position in Aurinia Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Tang Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.